Research Article

Association of Platelet Binding to Lymphocytes with B Cell Abnormalities and Clinical Manifestations in Systemic Lupus Erythematosus

Carlos Zamora, Elide Toniolo, Cesar Diaz-Torné, Elisabet Cantó, Berta Magallares, Ma Angels Ortiz, Lidia Perea, Hector Corominas, and Silvia Vidal

1Department of Immunology, Biomedical Research Institute Sant Pau (IBB Sant Pau), Barcelona, Spain
2Unit of Rheumatology, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain

Correspondence should be addressed to Carlos Zamora; czamora@santpau.cat and Silvia Vidal; svidal@santpau.cat

Received 25 September 2018; Revised 28 December 2018; Accepted 6 January 2019; Published 3 March 2019

Academic Editor: Emiliano Antiga

Copyright © 2019 Carlos Zamora et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Systemic lupus erythematosus (SLE) is an autoimmune disease associated with the polyclonal activation of B lymphocytes and the production of autoantibodies that cause immune complex-related inflammation. Immunological factors derived from platelets modulate B cell function in SLE disease. However, platelets do not only modify the immune system by soluble factors. The binding of platelets to lymphocytes can modulate immune response. Thus, we speculate that the binding of platelets to lymphocytes in SLE patients may play a role in abnormal B lymphocyte response and the pathogenesis of SLE. We observed that levels of lymphocytes with bound platelets were higher in SLE patients than in healthy donors (HD). In SLE patients, the percentage of B lymphocytes with bound platelets positively correlated with plasmatic levels of IgG, IgA, IL-10, and soluble CD40L and negatively correlated with IgM levels, though not in HD. Preswitched memory B lymphocytes were the subpopulation with more bound platelets. Lymphocytes with bound platelets from both HD and SLE patients had major levels of CD86 and BAFFR and a greater production of IL-10 than lymphocytes without bound platelets. However, only B lymphocytes with bound platelets from SLE patients had increased levels of IgG and IgA on their surface. SLE patients with a suggestive renal manifestation had the highest levels of B and T lymphocytes with bound platelets. These results suggest that the binding of platelets to lymphocytes plays a role in SLE disease and that controlling this binding may be a promising therapeutic approach.

1. Introduction

SLE has been associated with polyclonal B cell hyperactivity and autoantibody production [1–3]. B lymphocytes from SLE patients also display an increased expression of the activated markers CD86, CD80, and CD38 [4, 5] and IgG and IgA [6] levels on their surface. These patients have an elevated proportion of memory B lymphocytes and a decreased proportion of preswitched B lymphocytes [7, 8].

IL-10 is an anti-inflammatory cytokine secreted by Tregs, Bregs, Th2 lymphocytes, monocytes, and other cells that plays a crucial role in preventing inflammatory and autoimmune disease [9]. However, there is an elevated concentration of plasma IL-10 in SLE and these levels correlate with disease activity (SLEDAI) and the production of anti-dsDNA antibodies [10]. IL-10 has a positive influence on B cell survival, proliferation, differentiation, and autoantibody production [9]. Blocking IL-10 in SLE patients decreases autoantibody production and reduces clinical symptoms and disease activity [11, 12]. This IL-10 overproduction in SLE patients has been ascribed to B lymphocytes and monocytes [13]. Since B regulatory lymphocytes are the major B lymphocytes producing IL-10, they likely contribute to SLE pathogenesis [14, 15].

Platelet has recently been recognized as an immunoregulatory cellular component [16]. Upon activation, platelets release cytokines, chemokines, growth factors, and platelet-derived microparticles (PMP) and express a set of activation
molecules on their membrane (P-selectin and CD40L) that allow the platelet binding to leukocytes [17–20]. Platelets can bind to lymphocytes and P-selectin-PSGL-1 appears to be essential in this interaction. However, other molecules, such as CD40-CD40L, GPIb-CD11b, and GPIib/IIIa-CD11/CD18, can also play a role in the binding of platelet to lymphocytes [21]. Platelets directly modulate humoral activity, stimulating B cell proliferation, antibody production, and the membrane expression of CD27 and CD86, via soluble CD40L (sCD40L) [22, 23]. Both mechanisms, platelet-derived soluble factors (TGFβ, PF4, and sCD40L) and the binding of platelets to leukocytes (CD62P-PSGL1), decrease T cell proliferation and inflammatory cytokine production and increase IL-10 production by T lymphocytes and monocytes [18–20, 24, 25]. Through CD40-CD40L ligation, platelets support B cell isotype switching [23, 26] and, with the collaboration of Th cells, platelets enhance germinal center formation [27]. In fact, CD40L-deficient mice failed to elicited B cell isotype switch and this failure could be corrected by infusing CD40L-expressing platelets or platelet-free supernatant from activated platelets containing sCD40L [26]. Similarly, the blocking of CD40L in cocultures of platelets with B lymphocytes partially abolishes the binding of platelets to B lymphocytes [23]. In SLE patients, high levels of plasma sCD40L are observed, which are associated with disease severity and the development of nephritic lupus [28, 29]. sCD40L is released from platelet surface after its activation, and it is considered an in vivo marker of platelet activation [30, 31]. However, since CD40L is overexpressed on SLE T lymphocytes [28, 32, 33], and it can be shed from the membrane [34]; plasmatic sCD40L in SLE patients is not the sole product of platelets. An elevated number of circulating lymphocyte-platelet complexes and an increased platelet activation have been reported in patients with SLE and other autoimmune diseases [19, 35]. However, the binding of platelets to different lymphocyte subpopulations in SLE patients has not yet been studied and there is a lack of information about the relationship between platelet-binding to lymphocytes, lymphocyte function, and the clinical outcome of these patients.

Our aim was to analyze the possible role of lymphocyte-platelet complexes in the altered B cell function and SLE pathogenesis. Firstly, we compared the numbers of lymphocytes with bound platelets in SLE patients and healthy donors. Secondly, we established their relationship with platelet activation and the isotype class of autoantibodies and we investigated the phenotype and function of B lymphocytes with bound platelets in SLE patients. Finally, we established the relationship between lymphocytes with bound platelets and the clinical (hematuria and SLEDAI) and laboratory (anti-dsDNA, complement C3, and albumin/creatinine) features of patients.

2. Material and Methods

2.1. Study Subjects and Sample Collection. Whole blood from 16 healthy donors (HD) and 21 SLE patients was collected in BD vacutainer tubes containing heparin (BD, Franklin Lakes, NJ). SLE diagnosis was based on 1982 revised ACR criteria [36]. Two of the 21 patients did not meet to the Systemic Lupus International Collaborating Clinics (SLICC) criteria for SLE classification. Patients previously treated with B cell-targeted therapies, with other biologic agents, or with more than 10 mg per day of prednisone were excluded. To assess disease activity, patients’ Systemic Lupus Erythematosus Disease Activity Index (SLEDAI) was calculated at the time of the sample collection [37]. In Table 1, we show the demographic, clinical, and laboratory data of SLE patients enrolled in this study. Written informed consent was obtained, and ethical approval for the study was granted by the Hospital de la Santa Creu i Sant Pau Institutional Ethics Committee.

Peripheral blood mononuclear cells (PBMCs) were isolated by Ficoll–Hypaque density gradient (Lymphoprep, AXIS-SHIELD PoCAs, Oslo, Norway).

2.2. Staining of Peripheral Blood Mononuclear Cells and Whole Blood Cells. PBMCs (1 × 10⁶ cells) were incubated with anti-CD19-PED647, anti-CD38-PE, anti-CD41a-FITC, anti-CD41a-PE (Immunotools, Friesoythe, Germany), anti-CD19-PECy7, anti-CD27-APC, anti-BAFFR-FITC, anti-TACI-PE (BioLegend, San Diego, USA), anti-CD86-PE, anti-IgG-PE, anti-IgD-FITC (BD), anti-IgA-FITC, and anti-IgM-PE (Dako, CA, USA) mAbs and the corresponding isotype controls. Whole blood (100 μl) was incubated with anti-CD19-PECy7 (BioLegend), CD5-PE (BD Biosciences), CD19-PEC647, and CD41a-FTTC (Immunotools). Red blood cells were lysed, and white cells fixed using BD FACS lysing solution (BD Biosciences) to be analyzed by flow cytometry.

2.3. Flow Cytometry Analysis of Surface Markers and IL-10 Production. We were able to identify the main T and B lymphocyte subsets combining anti-CD19, anti-CD4, anti-CD8, and anti-CD5. Two subsets of B lymphocytes with bound platelets (PLTs) were identified as CD19+CD5-CD41a+ (CD19+PLT+) and CD19+CD5+CD41a+, respectively. CD4+ and CD8+ T lymphocytes with bound platelets were identified as CD19-CD4+CD5+CD41a+ (CD4+PLT+) and CD19-CD4-CD5+CD41a+ (CD8+PLT+), respectively, on gated lymphocytes. Activation markers and IL-10 production were analyzed on CD19+PLT+ and CD19+PLT- (B lymphocytes without bound platelets). CD19+ and CD19- lymphocytes that secreted spontaneously IL-10 were determined using IL-10 secretion assay (Miltenyi Biotec, Waltham, Massachusetts, USA). Then cells were washed, and membrane IL-10 was analyzed by flow cytometry. Briefly, after 4 h of resting, PBMCs were labeled with IL-10–specific catch reagent on their surface and incubated for 45 min at 37°C under slow rotation. Cells were washed and labeled with IL-10–PE detection antibody, CD19-PECy7 (BioLegend), CD41a-FITC (Immunotools), and viability marker LIVE/DEAD fixable Violet Dead Cell Stain kit (Thermo Fisher Scientific, Waltham, Massachusetts, USA). Then cells were washed, and membrane IL-10 was analyzed by flow cytometry. Percentages of viable lymphocytes did not differ between HD and SLE patients (90–95%). The percentage of CD19+ B lymphocyte subpopulations with or without bound platelets.
were defined as follows: naïve B lymphocytes (CD27-IgD+CD41+ and CD27-IgD+CD41-, respectively), preswitched memory B lymphocytes (CD27+IgD+CD41a+ and CD27+IgD+CD41a-, respectively), postswitched memory B lymphocytes (CD27-IgD-CD41a+ and CD27-IgD-CD41a-, respectively), and double-negative (DN) memory B lymphocytes (CD27-IgD-CD41a+ and CD27-IgD-CD41a-, respectively) [38]. Samples were acquired with the MACS-Quant Analyzer 10 flow cytometer (Miltenyi Biotec), and we determined the percentages of cells and the geometric mean fluorescence intensity (MFI) of BAFFR.

2.4. Quantification of Anti-dsDNA, Complement C3, Albumin/Creatinine, Hematuria, IgG, IgM, and IgA. Anti-dsDNA levels were determined in serum using Unicap Elia (Phadia Laboratory Systems, Uppsala, Sweden). Levels of complement C3 in serum and plasma IgG, IgM, and IgA were determined using the Nephelometry System (Beckman

| Table 1: Demographic, clinical, and laboratory characteristic data of study patients. |
|---------------------------------------------------------------|
| General conditions                                           |
| Age; year, mean ± SD                                         | 50.67 ± 12.58 | 49.06 ± 9.26 |
| Gender (%) (n) women                                         | 100 (21)      | 75 (12)      |
| Years of evolution, mean ± SD                                | 12.41 ± 10.29 |             |
| SLEDAI; mean (range)                                         | 2.62 (0-12)   |             |
| Laboratory parameters                                        |
| ESRa (mm/h, mean ± SD)                                       | 23.85 ± 20.02 |             |
| CRPB (mg/l, mean ± SD)                                       | 2.63 ± 3.48   |             |
| Complement C3 (mg/dl, mean ± SD)                             | 87.93 ± 20.86 |             |
| Complement C4 (mg/dl, mean ± SD)                             | 14.12 ± 4.49  |             |
| Decreased C3 or C4 (%) (n)                                   | 80.95 (17)    |             |
| Anti-dsDNA (U/ml), mean (range)                              | 74.8 (22-300) |             |
| Positive anti-dsDNA (%) (n)                                  | 42.8 (9)      |             |
| Positive ANA (%) (n)                                         | 95.23 (20)    |             |
| Positive anti-Sm (%) (n)                                     | 4.7 (1)       |             |
| Positive antiphospholipid antibody (%) (n)                   | 14.28 (3)     |             |
| Leukopenia and/or lymphopenia (%) (n)                        | 14.28 (3)     |             |
| Clinical features                                            |
| Renal involvement (%) (n)                                    | 23.8 (5)      |             |
| Hematuria                                                    | 23.8 (5)      |             |
| Albumin/creatinine > 2.5                                     | 23.8 (5)      |             |
| Cutaneous involvement (%) (n)                                | 28.57 (6)     |             |
| Oral or nasal ulcers                                         | 4.7 (1)       |             |
| Alopecia                                                     | 4.7 (1)       |             |
| Photosensitivity                                             | 23.8 (5)      |             |
| Butterfly erythema                                           | 9.5 (2)       |             |
| Arthritis (%) (n)                                            | 19.1 (4)      |             |
| Nervous system disorder                                      | 4.7 (1)       |             |
| Treatment (%) (n)                                            |
| None                                                         | 9 (2)         |             |
| Mycophenolate                                                | 14 (3)        |             |
| Prednisone                                                   | 48 (10)       |             |
| Hydroxychloroquine                                           | 62 (13)       |             |
| Azathioprine                                                 | 24 (5)        |             |
| Tacrolimus                                                   | 9 (2)         |             |
| NSAIDc                                                       | 14.28 (3)     |             |
| Aspirin                                                      | 23.8 (5)      |             |

aESR: erythrocyte sedimentation rate. bCRP: C-reactive protein. cNSAID: nonstereoidal anti-inflammatory drugs.
Coulter). Albumin/creatinine was determined in serum by the turbidimetry system (Abbott, Chicago, USA). The presence of hematuria was determined by the Combur test (Roche, Basilea, Switzerland). Anti-dsDNA antibodies were considered positive when levels were >17 UI/ml. Levels of albumin/creatinine were expressed as mg/mmol. Levels of complement C3 and immunoglobulins were expressed as mg/dl.

2.5. Determination of IL-10 and sCD40L. Plasma concentrations of IL-10 (Immunotools) and sCD40L (Peprotech, London, UK) were determined using specific ELISA kits according to the manufacturers’ instructions and using the specific standard curves of recombinant molecules. The limits of detection were as follows: 16 pg/ml for IL-10 and 31.25 pg/ml for sCD40L.

2.6. Statistics. The Kolmogorov-Smirnov test was applied to test the data for normal distribution. Normally distributed variables were then reported as mean ± s.e.m. Comparisons between groups were tested with Student’s t-test, the Mann-Whitney test, or the Wilcoxon test according to Gaussian distribution. ANOVA was used to compare more than two groups with normal distributions. Correlation analyses were carried out with Pearson’s correlation. p values < 0.05 were considered significant.

3. Results

3.1. Circulating Lymphocytes with Bound Platelets in SLE Patients. Higher percentages of circulating B and T lymphocytes with bound platelets were observed in SLE patients than in HD (Figures 1(a) and 1(b)). The percentages of bound platelets to the CD19+CD5+ B cell subpopulation in HD and SLE patients were comparable (7.15 ± 1.04 and 9.98 ± 1.54, respectively). In SLE patients but not in HD, T lymphocytes had more bound platelets than B lymphocytes (p < 0.01 for both CD4+ and CD8+ T lymphocytes). The percentages of B, CD4+, and CD8+ T lymphocytes with bound platelets correlated strongly to each other (r = 0.92, p < 0.0001 for %CD19+PLT+ vs. CD4+PLT+; r = 0.87, p < 0.0001 for %CD19+PLT+ vs. CD8+PLT+; and r = 0.91, p < 0.0001 for %CD4+PLT+ vs. CD8+PLT+). The percentage of B and T lymphocytes with bound platelets was not affected by the absolute numbers of lymphocytes and platelets (data not shown).

3.2. Association of B Lymphocytes with Bound Platelets with the Levels of Immunoglobulin and Platelet Activation. The percentage of CD19+PLT+ correlated positively with concentrations of IgG and IgA levels and correlated negatively with concentrations of IgM in SLE patients (Figures 2(a)–2(c)), though not with HD (r = 0.22, p = 0.52 for IgM;
r = 0.08, p = 0.81 for IgA; and r = 0.31, p = 0.39 for IgG). A positive correlation between the percentage of CD19+PLT+ and the IgG/IgM ratio was found in SLE patients (r = 0.56, p = 0.01) but not in HD. No differences in the plasma concentrations (mg/dl) of IgG, IgA, and IgM were observed between HD and SLE patients (IgG: 1083 ± 34.74 for HD vs. 1348 ± 125 for SLE; IgA: 262.2 ± 42.85 for HD vs. 319 ± 34.39 for SLE; IgM: 129.9 ± 16.55 for HD vs. 149.6 ± 20.76 for SLE). Plasma levels of sCD40L in SLE patients were higher than in HD (50.58 ± 25.79 pg/ml for HD vs. 691.3 ± 268.7 pg/ml for SLE, p < 0.01) and correlated with the percentage of each subpopulation of lymphocytes with bound platelets in SLE patients (Figures 2(d)–2(f)), though not in HD (r = 0.18, p = 0.66 for CD19+PLT+; r = 0.5, p = 0.25 for CD4+PLT+; and r = 0.28, p = 0.49 for CD8+PLT+). sCD40L also correlated with IgA levels in SLE patients (r = 0.52, p = 0.02).

3.3. Different Binding of Platelet to Preswitched Memory B Lymphocytes in SLE Patients. As expected [7, 8], SLE patients had a higher percentage of DN memory B lymphocytes but a lower percentage of preswitched memory B lymphocytes than HD (DN memory: 22.62 ± 2.52% for SLE vs. 12.76 ± 2.26% for HD, p < 0.05; preswitched memory: 3.31 ± 0.73% for SLE vs. 10.85 ± 1.91% for HD, p < 0.01). The percentages of naïve and postswitched memory B lymphocytes were comparable in SLE patients and HD. In the latter group, the different B lymphocyte subpopulations had a similar percentage of cells with bound platelets. However, in SLE patients, preswitched memory B lymphocytes showed a higher percentage of CD19+PLT+ lymphocytes compared with the other B lymphocytes subpopulations (p < 0.0001 by ANOVA) (Figures 3(a) and 3(b)).

No differences in the percentages of B lymphocytes with bound platelets were found between the whole blood and PBMC analysis of HD (5.31 ± 0.54 vs. 6.06 ± 0.85, respectively) and SLE (7.6 ± 1.04 vs. 8.15 ± 1.29, respectively).

3.4. Phenotype of B Lymphocytes with Bound Platelets in HD and SLE Patients. Only in SLE patients, CD19+PLT+ lymphocytes had higher percentages of IgG+ and IgA+ cells than CD19+PLT- lymphocytes (Figures 3(c) and 3(d)). In HD and SLE patients, CD19+PLT+ lymphocytes had higher percentages of CD86+ cells and expressed higher levels of BAFFR than the counterpart CD19+PLT- lymphocytes (Figures 3(e) and 3(f)). However, IgM, CD38, and TACI expressions were comparable on CD19+PLT+ and CD19+PLT- lymphocytes from SLE patients and HD (data not shown).

3.5. IL-10 Production by B Lymphocytes with and without Bound Platelets. After 4 h of resting in medium, CD19+PLT+ lymphocytes contained higher percentages of IL-10+ cells than CD19+PLT- lymphocytes in HD and SLE patients.
(Figure 4(a)). In SLE patients, we observed a tendency to a higher percentage of CD19+PLT+IL10+ lymphocytes than in HD (Figure 4(b)). No differences in the percentage of IL-10+ cells were observed in CD19- lymphocytes in HD and SLE patients (data not shown).

We then analyzed the association of plasma IL-10 concentration with platelet activation, measured as sCD40L concentration, and with the percentage of circulating lymphocytes with bound platelets. In SLE patients, IL-10 concentration correlated with sCD40L levels and with the percentages of CD19+PLT+, CD4+PLT+, and CD8+PLT+ cells (Figures 4(c)-(f)), but not in HD ($r = 0.33, p = 0.41$ for sCD40L; $r = 0.58, p = 0.12$ for CD19+PLT+; $r = 0.52, p = 0.18$ for CD4+PLT+, and $r = 0.67, p = 0.067$ for CD8+PLT+).

3.6. Relationship between Lymphocytes with Bound Platelets and Clinical Features. SLE patients with positive anti-dsDNA titers and those with hematuria had higher percentages of each subpopulation of lymphocytes with bound platelets than SLE patients with negative anti-dsDNA titers and without hematuria (Figures 5(a) and 5(b)). No correlation was found between the levels of anti-dsDNA antibodies and the percentage of CD19+PLT+. SLE patients with low complement C3 levels ($<85$ mg/dl) showed a higher percentage of CD19+PLT+ and a tendency to higher percentages of CD4+PLT+ and CD8+PLT+ than those with normal levels (85-193 mg/dl) (Figure 5(c)). SLE patients with albumin/creatinine levels $>2.5$ mg/mmol showed higher percentages of CD19+PLT+, CD4+PLT+, and CD8+PLT+ than those with normal levels ($\leq 2.5$ mg/mmol) (Figure 5(d)). SLE patients with SLEDAI $>3$ (patients with active disease suggestive of treatment change) [39, 40] showed higher percentages of CD19+PLT+, CD4+PLT+, and CD8+PLT+ than those with a SLEDAI $\leq 3$ (CD19+PLT+: $8.51 \pm 0.57$ for $>3$ vs. $6.43 \pm 0.49$ for $\leq 3$, $p = 0.02$; CD4+PLT+: $9.73 \pm 0.66$ for $>3$ vs. $7.11 \pm 0.64$ for $\leq 3$, $p = 0.02$; and CD8+PLT+: $9.49 \pm 0.59$ for $>3$ vs. $7.22 \pm 0.6$ for $\leq 3$, $p = 0.03$). Comparable percentages of each subpopulation of lymphocytes with bound platelets were observed when SLE patients were segregated according to medication and cutaneous or articular manifestations (data not shown).

4. Discussion

We found that the percentages of B lymphocytes with bound platelets were increased in SLE patients and correlated with plasma levels of sCD40L, IL-10, IgG, IgA, and IgM. B lymphocytes with bound platelets had upregulated activation markers and IL-10 production when compared to B lymphocytes without bound platelets. The highest percentages of lymphocytes with bound platelets were...
observed in SLE patients with positive anti-dsDNA and hematuria, a decreased complement C3, and an increased albumin/creatinine ratio. Our results suggest that the binding of platelets to lymphocytes could play a role in SLE disease through the modification of B cell function.

Joseph et al. described an increase in lymphocyte-platelet complexes and higher platelet activation in SLE patients [35]. However, these authors were unable to discriminate between different populations of lymphocytes. We have found that more B and T lymphocytes from SLE patients had bound platelets compared with HD and that these levels correlated with plasma sCD40L, a possible indirect measure of platelet activation [30, 31]. We have also found that T lymphocytes had more bound platelets than B lymphocytes in SLE patients suggesting a different interaction between platelets and T and B cells of SLE patients. Further experiments will reveal whether this increase is due to a particular T cell subset or a general increase of T cells with bound platelets in SLE. On the other hand, we did not analyze the activation state of free and bound platelets in these patients. It has been shown that the increased levels of plasma sCD40L indirectly indicate an increased platelet activation. However, CD40L is overexpressed on SLE T cells [28, 32, 33] and this molecule can be shed from the membrane of T lymphocytes [34], contributing to the soluble pool of sCD40L. On the other hand, using in vitro cultures, Danese et al. showed that platelets, but not T lymphocytes, from patients with inflammatory bowel diseases are the main source of the elevated sCD40L levels [41]. In addition, we also found in vitro cocultures that sCD40L increased proportionally to the platelet-PBMC ratio [20]. An increase in platelet activation markers such as thromboxane [42], soluble and surface P-selectin and CD40L [43, 44], and PMPs [45] in the blood of SLE patients has been observed in previous studies. Since we found that platelet activation was associated with platelet binding to lymphocytes in SLE and other authors found that platelet activation is directly associated with SLE disease activity [28, 29], it is likely that platelet binding modifies lymphocyte function and, consequently, plays a role in SLE. We and others have shown that platelet bound preferably to memory T lymphocytes [19, 46]. Therefore, the described expansion of memory and effector T lymphocytes in SLE patients [47] could explain the increased binding of platelets to SLE than to HD lymphocytes. Several pairs of molecules, such as PSGL-1-P-selectin, have been shown to be involved in the lymphocyte-platelet complex formation in HD. However, we did not find any correlation between PSGL-1 and the percentage of platelet-bound lymphocytes in other inflammatory diseases (unpublished work). According to some reports, a modification of PSGL-1, the alpha3 fucosylation of the O-glycans, is crucial for P-selectin binding and it is restricted to polarized T cells [48, 49]. Therefore, it is likely
that the analysis of fucosylated PSGL-1 could be more informative to understand the binding of platelets through P-selectin to SLE lymphocytes. In a different autoimmune context, we found that RA patients with the highest percentages of CD4+ cells with bound platelets had the lowest levels of IFNγ and IL-17 and the highest levels of plasma IL-10, with a less severe disease phenotype [19].

We found that the percentage of B lymphocytes with bound platelets and plasma sCD40L levels correlated with IgG and IgA levels and negatively correlated with IgM in SLE. It is well known that membrane CD40L, like sCD40L, is able to induce antibody production and signal B lymphocytes to switch IgG and IgA [22, 23, 26, 27]. With CD40L on the platelet surface, the binding of platelets to B lymphocytes [23] through CD40L-CD40 can induce the isotype switching. Accordingly, we found that B lymphocytes with bound platelets from SLE patients had higher membrane levels of IgG and IgA than B lymphocytes without bound platelets. An alternative explanation for our findings is that platelets bind preferentially to IgG+ and IgA+ B lymphocytes. Another intriguing result was that B lymphocytes without bound platelets from SLE patients had a higher expression of IgG and IgA than their counterparts from HD. This result could be related to the signal provided by the increased levels of sCD40L in the plasma of SLE patients.

**Figure 5:** Percentage of lymphocytes with bound platelets in SLE patients according to clinical features. Whole blood from SLE patients ($n=21$) was incubated with anti-CD4-PECy7, CD5-PE, CD19-PEDy647, and CD41a-FITC mAbs for flow cytometry analysis. Dot plots of percentages of CD19+ B lymphocytes and CD4+ and CD8+ T lymphocytes with bound platelets in SLE patients segregated according to (a) positive or negative anti-dsDNA, (b) positive or negative hematuria, (c) $<85$ or 85-193 mg/dl of C3, and (d) $>2.5$ or $\leq 2.5$ mg/mmol of albumin/creatinine are shown. Data are presented as the mean. Statistical analysis was performed using the Mann-Whitney test. $^* p < 0.05$, $^{**} p < 0.01$, and $^{***} p < 0.001$. 

Mediators of Inflammation
Despite the new numbers of preswitched memory, we showed that more preswitched memory B lymphocytes had bound platelets in SLE patients than in HD. In addition, more preswitched memory B lymphocytes in SLE patients had bound platelets than in other B lymphocytes. Our results suggest that the preswitched memory stage of B lymphocytes favors platelet binding. Two previous observations can explain these results. First, we found that B lymphocytes with bound platelets had an increased expression of CD86 and BAFFR compared with B lymphocytes without bound platelets. Second, preswitched memory B lymphocytes in SLE expressed higher levels of the activation markers, CD80, CD95, and CD86, than in HD, as shown by Rodriguez-Bayona et al. The affinity of platelets for activated lymphocytes does not seem to be a mechanism limited to B lymphocytes since we, along with other authors, have shown that platelets also bind preferentially to activated T lymphocytes [18, 19], favoring their binding to endothelium to migrate [50, 51]. However, with our current experiments, we cannot conclude whether the binding of platelet to B lymphocytes upregulates the expression of activation markers or platelets bind preferably to lymphocytes with an activated phenotype, such as preswitched memory. The addition of multiple activation markers for flow cytometry analysis will also reveal the full activated phenotype of the different subsets of B lymphocytes with bound platelets.

We showed that B lymphocytes with bound platelets had an increased percentage of IL-10-producing cells compared with B lymphocytes without bound platelets in SLE patients and HD. In addition, the plasma levels of IL-10 in SLE patients correlated with sCD40L plasma levels and the percentage of CD19+PLT+, CD4+PLT+, and CD8+ PLT+. IL-10 has been shown to play a positive role in B lymphocyte survival, proliferation, switching, and autoantibody production [9], contributing to SLE pathology. Accordingly, plasma IL-10 levels in SLE patients are increased and correlate with SLEDAI and the production of anti-dsDNA antibodies [10]. In addition, increased IL-10 production was observed in lupus nephritis patients [52]. Our results suggest that increased platelet activation and, consequently, the higher number of B lymphocytes with bound platelets could induce the increased IL-10 production of B cells with a detrimental role in the SLE course. However, with our current experiments, we cannot conclude whether platelets bind to B lymphocytes producing IL-10 or whether the binding of platelets to B lymphocytes increases the IL-10 production.

The highest percentages of B and T lymphocytes with bound platelets were found in those SLE patients with active disease and those with renal manifestations. Further studies with a large cohort of patients and consistent data relating to the involvement of different organs will be required to find associations between platelet bound and lymphocytes with different organ manifestations. Since platelet binding is a consequence of platelet activation, the activation of platelets must be associated with the development of lupus nephritis. In experimental models, targeting platelets markedly reduced mortality, proteinuria, kidney histological score, and the levels of anti-DNA antibodies [53, 54]. In SLE patients, platelet activation, measured as sCD40L, is directly related to disease activity and renal manifestations [28, 29]. No differences in the percentages of B and T lymphocytes with bound platelets were found in SLE patients with cutaneous, articular manifestations or when they were segregated according to medication, even when we segregated SLE patients taking antiaggregating drugs such as aspirin or hydroxychloroquine. However, this fact was not surprising because only clopidogrel, but not aspirin, reduces the formation of leukocyte-platelet complexes throughout decreasing P-selectin expression on platelets [55]. However, we cannot discard that medication of SLE patients could affect lymphocytes with bound platelets. A study of lymphocyte-platelet complexes in a large cohort of patients before and after taking antiaggregating drugs or patients with and without anti-phospholipids antibodies, which is known to be a potent platelet activator, will be required to study the modulation of these phenomena. We have demonstrated here that, in addition to the secretion of regulatory molecules, platelets can bind to lymphocytes in SLE. This binding is associated with an altered immune response, and these alterations are related to the clinical manifestations of SLE. However, one of our limitations is that we have excluded patients under a high dose of glucocorticoids (>10 mg/day) to avoid the influence of this treatment on our results. This exclusion could have biased the cohort to a less severe SLE, and it could explain the low frequency of patients with anti-dsDNA antibodies compared with other published cohorts. Another limitation is that lymphocyte-platelet complexes were analyzed at a one-time point in each patient. Further studies analyzing the same patient in a flare and in remission will be required to validate the potential of lymphocyte-platelet complexes as a tool to follow up SLE activity. With our current approach, we cannot discriminate if the increased percentage of B and T lymphocytes with bound platelets is involved in the development of SLE or if it is a consequence of the disease. Nevertheless, our findings suggest that controlling this binding is beneficial for the therapeutic regulation of autoimmunity.

5. Conclusions

Data in the current study show that SLE patients had a higher percentage of circulating lymphocytes with bound platelets than HD. This elevated percentage was associated with the plasmatic levels of Igs and IL-10 and sCD40L and B cell abnormalities described in SLE. In addition, SLE patients with suggestive renal manifestation and active disease had higher levels of lymphocytes with bound platelets. Taken all together, our findings suggest that the determination of the levels of circulating lymphocytes with bound platelets in SLE may prove to be a useful tool to follow up the activity of SLE disease and its renal manifestation. Moreover, controlling this binding may prove to be beneficial for the therapeutic regulation of autoimmunity.

Abbreviations

CD: Cluster differentiation
dsDNA: Double-stranded DNA
HD: Healthy donors
IL: Interleukin
Ig: Immunoglobulin
mAbs: Monoclonal antibodies
PBMCs: Peripheral blood mononuclear cells
PLT: Platelets
PMP: Platelet-derived microparticles
SLE: Systemic lupus erythematosus
sCD40L: Soluble CD40L
SLEDAI: Systemic Lupus Erythematosus Disease Activity Index
TGFβ: Transforming growth factor beta.

Data Availability

The data used to support the findings of this study are available from the corresponding author upon request.

Conflicts of Interest

The authors declare no conflicts of interest.

Authors’ Contributions

All authors were involved in revising the text critically for important intellectual content, and all authors approved the final version to be published. CZ and SV are responsible for the study conception and design. ET, CD-T, BM, and HC collected the samples and clinical parameters. CZ, ET, EC, MAO, and LP acquired the data. CZ, ET, CD-T, and SVA are responsible for the analysis and interpretation of data. CZ and SV drafted the article.

Acknowledgments

This work was supported by the Instituto de Salud Carlos III (grant numbers PI14/741 and PI17/072). SV was supported by “Fondo Investigaciones Sanitarias” and participated in the Program for Stabilization of Investigators by the “Direcció i d’Estrategia i Coordinació del Departament Salut de la Generalitat de Catalunya.”

References

[1] G. C. Tsokos, “Systemic lupus erythematosus,” The New England Journal of Medicine, vol. 365, no. 22, pp. 2110–2121, 2011.
[2] T. Dörner, C. Giesecke, and P. E. Lipsky, “Mechanisms of B cell autoimmunity in SLE,” Arthritis Research & Therapy, vol. 13, no. 5, p. 243, 2011.
[3] D. Koffler, V. Agnello, R. Thoburn, and H. G. Kunkel, “Systemic lupus erythematosus: prototype of immune complex nephritis in man,” The Journal of Experimental Medicine, vol. 134, no. 3, pp. 169–179, 1971.
[4] N.-H. Chang, T. McKenzie, G. Bonventi et al., “Expanded population of activated antigen-engaged cells within the naive B cell compartment of patients with systemic lupus erythematosus,” Journal of Immunology, vol. 180, no. 2, pp. 1276–1284, 2008.
[5] M. Bijl, G. Horst, P. Limburg, and C. Kallenberg, “Expression of costimulatory molecules on peripheral blood lymphocytes of patients with systemic lupus erythematosus,” Annals of the Rheumatic Diseases, vol. 60, no. 5, pp. 523–526, 2001.
[6] H. Joo, C. Coquery, Y. Xue et al., “Serum from patients with SLE instructs monocytes to promote IgG and IgA plasmablast differentiation,” The Journal of Experimental Medicine, vol. 209, no. 7, pp. 1335–1348, 2012.
[7] B. Rodriguez-Bayona, A. Ramos-Amaya, J. J. Perez-Venegas, C. Rodriguez, and J. A. Brieva, “Decreased frequency and activated phenotype of blood CD27 IgD IgM B lymphocytes is a permanent abnormality in systemic lupus erythematosus patients,” Arthritis Research & Therapy, vol. 12, no. 3, p. R108, 2010.
[8] M. Odendahl, A. Jacobi, A. Hansen et al., “Disturbed peripheral B lymphocyte homeostasis in systemic lupus erythematosus,” The Journal of Immunology, vol. 165, no. 10, pp. 5970–5979, 2000.
[9] W. Ouyang, S. Rutz, N. K. Crelin, P. A. Valdez, and S. G. Hymowitz, “Regulation and functions of the IL-10 family of cytokines in inflammation and disease,” Annual Review of Immunology, vol. 29, no. 1, pp. 71–109, 2011.
[10] F. Houssiau, C. Lefebvre, M. Vanden Berghe, M. Lambert, J.-P. Devogelaer, and J.-C. Renauld, “Serum interleukin 10 titers in systemic lupus erythematosus reflect disease activity,” Lupus, vol. 4, no. 5, pp. 393–395, 1995.
[11] L. Llorente, W. Zou, Y. Levy et al., “Role of interleukin 10 in the B lymphocyte hyperactivity and autoantibody production of human systemic lupus erythematosus,” The Journal of Experimental Medicine, vol. 181, no. 3, pp. 839–844, 1995.
[12] L. Llorente, Y. Richaud-Patin, C. García-Padilla et al., “Clinical and biological effects of anti-interleukin-10 monoclonal antibody administration in systemic lupus erythematosus,” Arthritis and Rheumatism, vol. 43, no. 8, pp. 1790–1800, 2000.
[13] L. Llorente, Y. Richaud-Patin, J. Wijdenes et al., “Spontaneous production of interleukin-10 by B lymphocytes and monocytes in systemic lupus erythematosus,” European Cytokine Network, vol. 4, pp. 421–427, 1993.
[14] X. Yang, J. Yang, Y. Chu et al., “T follicular helper cells and regulatory B cells dynamics in systemic lupus erythematosus,” PLoS One, vol. 9, no. 2, article e84411, 2014.
[15] D. Sakurai, J. Zhao, Y. Deng et al., “Preferential binding to Elk-1 by SLE-associated IL10 risk allele upregulates IL10 expression,” PLoS Genetics, vol. 9, no. 10, article e1003870, 2013.
[16] J. W. Semple, J. E. Italiano, and J. Freedman, “Platelets and the immune continuum,” Nature Reviews Immunology, vol. 11, no. 4, pp. 264–274, 2011.
[17] A. McNicol and S. J. Israels, “Beyond hemostasis: the role of platelets in inflammation, malignancy and infection,” Cardiovascular & Hematological Disorders Drug Targets, vol. 8, no. 2, pp. 99–117, 2008.
[18] S. Dinkla, B. van Cranenbroek, W. A. van der Heijden et al., “Platelet microparticles inhibit IL-17 production by regulatory T cells through P-selectin,” Blood, vol. 127, no. 16, pp. 1976–1986, 2016.
[19] C. Zamora, E. Cantó, J. C. Nieto et al., “Functional consequences of platelet binding to T lymphocytes in inflammation,” Journal of Leukocyte Biology, vol. 94, no. 3, pp. 521-529, 2013.
[20] C. Zamora, E. Cantó, J. C. Nieto et al., “Binding of platelets to lymphocytes: a potential anti-inflammatory therapy in rheumatoid arthritis,” *Journal of Immunology*, vol. 198, no. 8, pp. 3099–3108, 2017.

[21] N. Li, Q. Ji, and P. Hjemdahl, “Platelet-lymphocyte conjugation differs between lymphocyte subpopulations,” *Journal of Thrombosis and Haemostasis*, vol. 4, no. 4, pp. 874–881, 2006.

[22] A. Solanilla, J.-M. Pasquet, J.-F. Viallard et al., “Platelet-associated CD154 in immune thrombocytopenic purpura,” *Blood*, vol. 105, no. 1, pp. 215–218, 2005.

[23] F. Cognasne, H. Hamzeh-Cognasse, S. Lafarge et al., “Human platelets can activate peripheral blood B cells and increase production of immunoglobulins,” *Experimental Hematology*, vol. 35, no. 9, pp. 1376–1387, 2007.

[24] S. Guibrandsdottrir, H. C. Hasselbalch, and C. H. Nielsen, “Activated platelets enhance IL-10 secretion and reduce TNF-α secretion by monocytes,” *The Journal of Immunology*, vol. 191, no. 8, pp. 4059–4067, 2013.

[25] C. Y. Liu, M. Battaglia, S. H. Lee, Q.-H. Sun, R. H. Aster, and G. P. Visentin, “Platelet factor 4 differentially modulates CD4⁺CD25⁺ (regulatory) versus CD4⁺CD25⁻ (nonregulatory) T cells,” *The Journal of Immunology*, vol. 174, no. 5, pp. 2680–2686, 2005.

[26] B. D. Elzeu, J. Tian, R. J. Jensen et al., “Platelet-mediated modulation of adaptive immunity. A communication link between innate and adaptive immune compartments,” *Immunity*, vol. 19, no. 1, pp. 9–19, 2003.

[27] B. D. Elzeu, J. F. Grant, H. W. Sinn, B. Nieswandt, T. J. Waldschmidt, and T. L. Ratliff, “Cooperation between platelet-derived CD154 and CD4⁺ T cells for enhanced germinal center formation,” *Journal of Leukocyte Biology*, vol. 78, no. 1, pp. 80–84, 2005.

[28] M. Koshy, D. Berger, and M. K. Crow, “Increased expression of CD40 ligand on systemic lupus erythematosus lymphocytes,” *The Journal of Clinical Investigation*, vol. 98, no. 3, pp. 826–837, 1996.

[29] S. S. ElGendi and W. T. El-Sherif, “Anti-C1q antibodies, sCD40L, TWEAK and CD4/CD8 ratio in systemic lupus erythematosus and their relations to disease activity and renal involvement,” *The Egyptian Journal of Immunology*, vol. 16, no. 1, pp. 135–148, 2009.

[30] M. Saboor, Q. Ayub, S. Ilyas, and Mooinuddin, “Platelet receptors: an instrumental of platelet physiology,” *Pakistan Journal of Medical Sciences*, vol. 29, no. 3, pp. 891–896, 2013.

[31] K. Jurk and B. E. Kehrel, “Platelets: physiology and biochemistry,” *Seminars in Thrombosis and Hemostasis*, vol. 31, no. 04, pp. 381–392, 2005.

[32] C. G. Katsiari, S.-N. Liossis, A. M. Dimopoulos, D. V. Charalambopoulos, M. Pavritkakis, and P. P. Sifakis, “CD40L overexpression on T cells and monocytes from patients with systemic lupus erythematosus is resistant to calcineurin inhibition,” *Lupus*, vol. 11, no. 6, pp. 370–378, 2002.

[33] A. Desai-Mehta, L. Lu, R. Ramsey-Goldman, and S. K. Datta, “Hypexpression of CD40 ligand by B and T cells in human lupus and its role in pathogenic autoantibody production,” *The Journal of Clinical Investigation*, vol. 97, no. 9, pp. 2063–2073, 1996.

[34] F. Pietravalle, S. Leconet-Henchoz, H. Blacey et al., “Human native soluble CD40L is a biologically active trimer, processed inside microsomes,” *The Journal of Biological Chemistry*, vol. 271, no. 11, pp. 5965–5967, 1996.

[35] J. E. Joseph, P. Harrison, I. J. Mackie, D. A. Isenberg, and S. J. Machin, “Increased circulating platelet-leucocyte complexes and platelet activation in patients with antiphospholipid syndrome, systemic lupus erythematosus and rheumatoid arthritis,” *British Journal of Haematology*, vol. 115, no. 2, pp. 451–459, 2001.

[36] E. M. Tan, A. S. Cohen, J. F. Fries et al., “The 1982 revised criteria for the classification of systemic lupus erythematosus,” *Arthritis and Rheumatism*, vol. 25, no. 11, pp. 1271–1277, 1982.

[37] J. Guzmán, M. H. Cardiel, A. Arce-Salinas, J. Sánchez-Guerrero, and D. Alarcón-Segovia, “Measurement of disease activity in systemic lupus erythematosus. Prospective validation of 3 clinical indices,” *The Journal of Rheumatology*, vol. 19, no. 10, pp. 1551–1558, 1992.

[38] U. Klein, K. Rajewsky, and R. Küppers, “Human immunoglobulin (Ig)M/IgD⁺ peripheral blood B cells expressing the CD27 surface antigen carry somatically mutated variable region genes: CD27 as a general marker for somatically mutated (memory) B cells,” *Journal of Experimental Medicine*, vol. 188, no. 9, pp. 1679–1689, 1998.

[39] M. Petri, “Disease activity assessment in SLE: do we have the right instruments?,” *Ann Rheum Dis*, vol. 66, Supplement 3, pp. iii61–iii64, 2007.

[40] E. E. Perez-Guerrero, J. I. Gamez-Nava, J. F. Muñoz-Valle et al., “Serum levels of P-glycoprotein and persistence of disease activity despite treatment in patients with systemic lupus erythematosus,” *Clinical and Experimental Medicine*, vol. 18, no. 1, pp. 109–117, 2018.

[41] S. Danese, J. A. Katz, S. Saini et al., “Activated platelets are the source of elevated levels of soluble CD40 ligand in the circulation of inflammatory bowel disease patients,” *Gut*, vol. 52, no. 10, pp. 1435–1441, 2003.

[42] D. Ferro, S. Basili, S. Roccaforte et al., “Determinants of enhanced thromboxane biosynthesis in patients with systemic lupus erythematosus,” *Arthritis and Rheumatism*, vol. 42, no. 12, pp. 2689–2697, 1999.

[43] K. Kato, E. Santana-Sahagún, L. Z. Rassenti et al., “The soluble CD40 ligand sCD154 in systemic lupus erythematosus,” *The Journal of Clinical Investigation*, vol. 104, no. 7, pp. 947–955, 1999.

[44] A. Goules, A. G. Tzioufas, M. N. Manousakis, K. A. Kirou, M. K. Crow, and J. G. Routsias, “Elevated levels of soluble CD40 ligand (sCD40L) in serum of patients with systemic autoimmune diseases,” *Journal of Autoimmunity*, vol. 26, no. 3, pp. 165–171, 2006.

[45] J. Sellam, V. Proulle, A. Jüngel et al., “Increased levels of circulating microparticles in primary Sjögren’s syndrome, systemic lupus erythematosus and rheumatoid arthritis and relation with disease activity,” *Arthritis Research & Therapy*, vol. 11, no. 5, p. R156, 2009.

[46] S. A. Green, M. Smith, R. B. Hasley et al., “Disease activity and damage indexes,” *Lupus*, vol. 27, no. 1, pp. 143–149, 2018.

[47] C. A. van Wely, A. D. Blanchard, and C. J. Britten, “Differential expression of α3 fucosyltransferases in Th1 and Th2 cells correlates with their ability to bind P-selectin,” *Biochemical*
12 Mediators of Inflammation

and Biophysical Research Communications, vol. 247, no. 2, pp. 307–311, 1998.

[49] F. Austrup, D. Vestweber, E. Borges et al., “P- and E-selectin mediate recruitment of T-helper-1 but not T-helper-2 cells into inflamed tissues,” Nature, vol. 385, no. 6611, pp. 81–83, 1997.

[50] T. G. Diacovo, K. D. Puri, R. A. Warnock, T. A. Springer, and U. H. von Andrian, “Platelet-mediated lymphocyte delivery to high endothelial venules,” Science, vol. 273, no. 5272, pp. 252–255, 1996.

[51] T. G. Diacovo, M. D. Catalina, M. H. Siegelman, and U. H. von Andrian, “Circulating activated platelets reconstitute lymphocyte homing and immunity in L-selectin-deficient mice,” Journal of Experimental Medicine, vol. 187, no. 2, pp. 197–204, 1998.

[52] L. Zhi-Chun, Z. Qiao-Ling, L. Zhi-Qin, L. Xiao-Zhao, Z. Xiao-xia, and T. Rong, “Tumor necrosis factor-like weak inducer of apoptosis (TWEAK) mediates p38 mitogen-activated protein kinase activation and signal transduction in peripheral blood mononuclear cells from patients with lupus nephritis,” Inflammation, vol. 35, no. 3, pp. 935–943, 2012.

[53] P. Duffau, J. Seneschal, C. Nicco et al., “Platelet CD154 potentiates interferon-α secretion by plasmacytoid dendritic cells in systemic lupus erythematosus,” Science Translational Medicine, vol. 2, no. 47, article 47ra63, 2010.

[54] C. Zoja and G. Remuzzi, “Role of platelets in progressive glomerular diseases,” Pediatric Nephrology, vol. 9, no. 4, pp. 495–502, 1995.

[55] U. Klinkhardt, R. Bauersachs, J. Adams, J. Graff, E. Lindhoﬀ-Last, and S. Harder, “Clopidogrel but not aspirin reduces P-selectin expression and formation of platelet-leukocyte aggregates in patients with atherosclerotic vascular disease,” Clinical Pharmacology and Therapeutics, vol. 73, no. 3, pp. 232–241, 2003.